Update on conventional thiopurine management in IBD

Frank Hoentjen*, Nanne K.H. De Boer

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Conventional thiopurine therapy with azathioprine or 6-mercaptopurine is an important maintenance strategy in IBD. Unfortunately, many patients have to discontinue this therapy owing to adverse events or lack of efficacy. Given the limited options for alternative maintenance therapies in IBD, as well as our increasing knowledge of thiopurine metabolism, optimizing thiopurine therapy has become an important area of investigation - with the aim of avoiding the need for discontinuation of therapy. In this review, we will discuss recent advances in our understanding of thiopurine metabolism, pharmacogenomics, therapeutic drug monitoring, safety issues, and drug interaction.

Original languageEnglish
Pages (from-to)135-142
Number of pages8
JournalInflammatory Bowel Disease Monitor
Volume12
Issue number4
Publication statusPublished - 1 Dec 2012

Cite this